Today: November 26, 2015, 1:27 am

Pakistan pharmaceutical market: New market research published
The Pharmaceutical Market: Pakistan - a new market research report on 2014-03-13 15:10:02
For new medicines to be launched into the Pakistani market, the pharmaceutical regulator must drop its requirement for local rigorous drug approvals and registration process. The country does not have the necessary number of trained professionals to effectively monitor the costly and timely process, while patients would benefit from more rapidly introduced pharmaceuticals. Drugmakers would also see higher commercial upside if the requirements were withdrawn.

Headline Expenditure Projections

Pharmaceuticals : PKR171.20bn (US$1.98bn) in 2011 to PRK189.22bn (US2.05bn) in 2012; +10.5% in local currency terms and +3.2% in US dollar terms.

Healthcare: PKR361.13bn (US$4.18bn) in 2011 to PKR399.54bn (US$4.32bn) in 2012; +10.5% in local currency terms and +6.9% in US dollar terms.

Medical devices: PKR35.14bn (US$407mn) in 2011 to PKR40.48bn (US$438mn) in 2012; +14.8% in local currency terms and +11.1% in US dollar terms.

Risk/Reward Ratings

We continue to expect improving healthcare provision in Asia Pacific to bring opportunities for pharmaceutical and medical devices players due to a wider pool of patients. However, the success of these healthcare services depends on its implementation and subsequent monitoring. We highlight that not all countries will be able to succeed in their quest for better healthcare due to poor governance. Aligning with this, in B M I´s Asia Pacific Risk/Reward Ratings (RRRs) for Q113, Pakistan has maintained its rank of a poor 16th out of the 18 markets in the regional matrix. Pakistan ranks below the regional averages for both composite risk and reward figures, in spite of its large and growing population.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 490 Words
Related Articles
More From Finance
USGFX Anticipates A Rise In Forex Trading [..]
The Shanghai Composite Index has been volatile and at one stage dropped more than 30% from its June 12 peak, [..]
Credit-Yogi Recommends Reputable Debt Solution Companies To [..]
Many people who have poor credit don’t know what to do about it. They realize that their bad credit prevents [..]
Credit-Yogi Reveals Special Considerations for Military Members [..]
No one wants to have their vehicle taken back by their banks. It’s a source of stress for the individual [..]
Credit-Yogi Teaches Consumers How To Use HAMP [..]
Be Prepared to Utilize HAMP Lenders do not like to help borrowers prevent foreclosure by accessing the Obama loan modification [..]
Credit-Yogi Informs Military Members Facing Auto Repossession [..]
No one wants to have their vehicle taken back by their banks. It’s a source of stress for the individual [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.